L.A. Lesmana Department of Medicine, University of Indonesia, Jakarta.

Slides:



Advertisements
Similar presentations
Hcv infection and management in advanced liver disease
Advertisements

Alfredo ALBERTI. How to predict outcome in hepatitis C patients Alfredo Alberti Department of Clinical and Experimental Medicine Venetian Institute of.
1 Prediabetes Screening and Monitoring. 2 Prediabetes Epidemiologic evidence suggests that the complications of T2DM begin early in the progression from.
Francesco NEGRO. Steatosis and Chronic Hepatitis C: liaisons dangéreuses? Francesco Negro Unité de Viropathologie Centre Médical Universitaire Genève.
Treatment appropriate Normal or minimal hepatitis Chronic hepatitis Normal or inactive hepatitis Progressive fibrosis Cirrhosis HCC HBeAg Anti-HBe HBV.
Nezam AFDHAL. Initial Presentation  47-year-old white male  Ex-IVDU 20 years ago  Alcohol >20 g/day for 8 years, none for 18 years  Asymptomatic apart.
Predictors of elevated transaminase levels in patients with central obesity V. Papastergiou, G. Ntetskas, L. Skorda, F. Lambrianou, K. Roufas, E. Asonitis,
Natural History of Hepatitis B and Liver Cancer Screening Herbert H Lee, M.D., M.P.H., M.S.Ed.
Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV Recurrence Following Liver Transplantation Phase 2 Charlton M, et al. Gastroenterology.
S_khalilzadeh. NAFLD and T2DM NAFLD is closely associated with features of the metabolic syndrome and is regarded as the hepatic manifestation of the.
3 rd Paris Hepatitis Conference January, 20th 2009 How to optimize the management of my HBeAg negative patients? Pietro Lampertico 1st Gastroenterology.
Results Table 1: Factors associated with advanced liver fibrosis in univariable analysis among 216 chronic HCV patients Background There is a clinical.
Metabolic Factors / NAFLD on the Natural History of Chronic Hepatitis B or C in Asia Pei-Jer Chen National Taiwan University & Hospital.
How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.
Hepatitis C Virus Infection Hepatitis C Virus Infection Burden of Disease in United States New infections (cases)/year , ,000 Persons.
METABOLIC Syndrome: a Global Perspective
Chronic Hepatitis B Diagnosis When to refer
SERUM VISFATIN CONCENTRATION IS ASSOCIATED WITH AN ATHEROGENIC METABOLIC PROFILE T.D. Filippatos 1, A. Liontos 1, F. Barkas 1, E. Klouras 1, V. Tsimihodimos.
Clinicaloptions.com/hepatitis Serum HBsAg as a Predictor of Response to PegIFN in HBeAg-Positive Patients Slideset on: Chan HL, Wong VW, Chim AM, Chan.
HBV genotyping 12/21/07 Carrie Marshall. Received a send-out request for HBV genotyping on a 52y man.
OBV/PTV/r + DSV + RBV Placebo Randomisation** 3 : 1 Double blind years Chronic HCV genotype 1 HCV RNA ≥ 10,000 IU/ml Failure to pre-treatment with.
Diabetes National Diabetes Control Programme
Triglycerides,LDL cholesterol and HOMA score predict the virological response in HIV/HCV co-infected patients treated with Pegylated interferon alpha 2a.
Farid Saad Euro Weight Loss-2015 Frankfurt, Germany August 18 – 20, 2015.
COSMOS SOF + SMV + RBV SOF + SMV Randomisation 2 : 1 : 2 : 1* Open-label * Randomisation was stratified on genotype (1a or 1b) in both cohorts, IL28B in.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
How to manage G1 relapsers and non-responders George V. Papatheodoridis, MD Associate Professor in Medicine & Gastroenterology 2nd Department of Internal.
Dr. I. Selvaraj Indian Railways Medical Service B.Sc., M.B.B.S., M.D.,D.P.H., D.I.H., PGCHFW ( NIHFW,New Delhi)., Life member of Indian Association of.
Sources of Hepatitis C Infection (U.S.) Previously Acquired (
Insulin Resistance Progression to Diabetes. Hypertension: BP >140/90 Dyslipidemia: ◦TG >150 mg/dL (1.7 mmol.L) ◦HDL-C
W24 ≥ 18 years Chronic HCV infection Genotype 1 Treatment naïve Early fibrosis to compensated cirrhosis No HBV or HIV co-infection N = 10 SOF + weight-based.
SOLAR-2 LDV/SOF + RBV Randomisation of the 7 groups 1 : 1 Open-label SOLAR-2 Study: LDV/SOF + RBV in decompensated and post-liver transplant with genotype.
No randomization N = 59 W12W24 Arm B : compensated cirrhosis N = 31 N = 29 Arm C : compensated cirrhosis Arm A : No cirrhosis AGATE-II Study: OBV/PTV/r.
SMV + DCV + SOF Open label Chronic HCV infection Genotype 1 or 4 Treatment-naïve or pre-treated with PEG-IFN ± RBV Portal hypertension or liver decompensation.
OBV/PTV/r + DSV Open label Chronic HCV infection Genotype 1 Treatment-naïve HCV RNA > 1,000 IU/ml Chronic kidney disease with eGFR < 30 ml/min/1.73m 2.
No randomisation Open-label years HCV genotype 1 Naïve or null-response to PEG-IFN + RBV HCV RNA > 10,000 IU/ml No cirrhosis No HBV or HIV co-infection.
Asselah T. AASLD 2015, Abs OSIRIS  Design SMV + PEG-IFN + RBV Open label Chronic HCV infection Genotype 4 Treatment-naïve Mild to moderate fibrosis.
 Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, next observation carried backward DCV + SOF + RBV Randomised* 1:1 Open-label ALLY-3+ study: DCV.
SAPPHIRE-I Feld JJ. NEJM 2014;370: SAPPHIRE-I Study: ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin for genotype 1  Treatment regimens.
내과스텝강의 국내 만성B형간염의 현황과 치료 전략.
Nonalcoholic Fatty Liver Disease / Nonalcoholic Steatohepatitis 소화기내과 R3 신아리 1.
The short term effects of metabolic syndrome and its components on all-cause-cause mortality-the Taipei Elderly Health Examination Cohort Wen-Liang Liu.
Previous SVR With Interferon-Based Therapy for HCV Lowers Risk of Hepatotoxicity in HIV/HCV-Coinfected Individuals on Antiretroviral Therapy Slideset on:
Clinicaloptions.com/hepatitis NAFLD and NASH Prevalence in US Cohort Slideset on: Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty.
W. Ray Kim, MD Associate Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic College of Medicine Rochester, Minnesota Clinical.
Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH.
PREVALENCE AND RISK FACTORS FOR NON- ALCOHOLIC FATTY LIVER DISEASE AMONG AN URBAN AGING ADULT SRI LANKAN POPULATION– RAGAMA HEALTH STUDY 7-YEAR FOLLOW.
HBV. Overview of the Epidemiology of Hepatotropic Viruses.
Journal Conference Hepatology 2009;50: Background.
Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.
Predictor factors associated with liver fibrosis and steatosis by transient elastography in HIV mono-infected patients under long-term combined antiretroviral.
results of the METAFIB study
GARNET Study: OBV/PTV/r + DSV 8 weeks in genotype 1b
Creatinine clearance ≥ 50 ml/min No HBV or HIV co-infection
HCV & liver transplantation
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Risks and Assessment NHLBI Obesity Education.
Screening and Monitoring
More Than Meets the Eye: Identifying Who Is at Risk for NASH
Phase 3 Treatment-Naïve and Treatment-Experienced
Phase 3 Treatment-Naïve and Treatment-Experienced
Type 2 diabetes: Overlap of clinical conditions
ARV-trial.com IMPACT Study: SMV + DCV + SOF in HCV genotype 1 with decompensated liver disease Design Open label ≥ 18 years Chronic HCV infection Genotype.
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Impact of metabolic risk factors on HCC
‘Easy to treat’ genotypes were not created equal: Can rapid virological response (RVR) level the playing field?  Andres Duarte-Rojo, Elizabeth Jenny Heathcote,
Clinicaloptions.com/hepatitis Using Virologic and Serologic Tests in the Management of Hepatitis B Diagnose chronic HBV infection When in slideshow mode,
Progression of chronic Hepatitis B From beginning to end
Selonsertib in NASH: phase 2
ENDURANCE-4 Study: glecaprevir/pibrentasvir in genotype 4, 5 or 6
Comparison of the Biochemical Responses between TAF and TDF in CHB
Presentation transcript:

L.A. Lesmana Department of Medicine, University of Indonesia, Jakarta

NALFD – AASLD definition 2012 Evidence of hepatic steatosis, by imaging or by histology, No causes for secondary hepatic fat accumulation Chalasani N, et al. Gastroenterology 2012;142:

Prevalence of NAFLD in the Asia-Pacific region Country Percentage of NAFLD Country Percentage of NAFLD Japan 9 – 30% Japan 9 – 30% China 5 – 18% China 5 – 18% Korea 18 % Korea 18 % India 5 – 28% India 5 – 28% Indonesia 30% Indonesia 30% Malaysia 17 % Malaysia 17 % Singapore 5% Singapore 5% Amarapurkar. Asia Pacific Working Party on NAFLD 2006

Insulin Resistance and Hepatitis p<0.005 Imazeki et al. Liver Int 2008:355-62

Current Evidence

Prevalence of steatosis in CHB StudiesYearCountryNumber of casess Prevalence of steatosis (%) Altlparmak et al.2005Turkey16439 Gordon et al.2005Australia1776 Thomopulos et al.2006Greece23318 Bondini et al2007USA15332 Peng et al2008China15327 Rastogi et al2011India35034 Lesmana et al2012Indonesia17430 Thomopoulos KC, et al. Eur J Gastroenterol Hepatol 2006;18:233-7 Altlparmak E, et al. World J Gastroenterol 2005;11: Gordon A, et al. J Hepatol 2005;43: Peng D, et al. J Gastroenterol Hepatol 2008;23: Bondini S, et al. Liver Int 2007;27: Rastogi A. et al. Indian J Pathol Microbiol 2011;54: Lesmana LA, et al. Acta Med Indones 2012;44:35-9.

Factors associated with FL in CHB Fatty Liver (-) (n=100) Fatty Liver (+) (n=64) p-value Mean age (years) Mean BMI (kg/m 2 ) Male sex, n(%)60 (53.1)53 (46.9)0.008 Mean AST (U/L) Mean ALT (U/L) Mean cholesterol (mg/dL) ) Mean triglyceride (mg/dL) HBeAg positive, n(%)42 (41.4)17 (27.0)0.059 Mean viral load (pg/mL)1, Fibrosis stage 2-3, n(%)20 (20)11 (17.2)0.754 HAI 9-17, n(%)36 (36)23 (35.9)0.772 Altlrmak E, et al. World J Gastroenterol 2005;11:

Insulin Resistance in CHB HOMA-IR <1.64 (n=35) HOMA-IR > 1.64 (n=34) p-value Mean BMI (kg/m 2 ) Mean waist circumference (cm) Median triglyceride (mg/dL) Median fasting insulin (μU/mL) <0.001 Fasting glucose (mg/dL)8553<0.001 Fibrosis F2-F4, n(%)21 (60.0)15 (54.2)0.232 HAI >6, n(%)11 (31.4)10 (29.4)0.717 Steatosis grade (57.2)21 (61.8)0.873 Median HBV-DNA (log copies/mL) HBeAg positive, n(%)13 (37.1)13 (38.2)1.000 Kumar M, et al. Am J Gastroenterol 2009;104:76-82.

Demographic Factors VariableSteatosis (+) (n=118) Steatosis (-) (n=232) p value Mean age <0.001 Male : Female108 : : Rastogi A. et al. Indian J Pathol Microbiol 2011;54: VariableSteatosis (+) (n=52) Steatosis (-) (n=122) p valueOR (95%CI) Mean age Male : Female (%)73.1 : : (1,38-5,69) Medistra Hospital. Unpublished data

Biochemical and Viral Factors VariableSteatosis (+) (n=118) Steatosis (-) (n=232) p value Median ALT (U/mL) HBeAg positive (%) Median DNA (copies/mL)69 x x HBV genotypes (n=80): A B C D A+C A+D A+C+D 12.6% % 3.1% % 2.1% 64.6% 2.1% 12.5% 2.1% Rastogi A. et al. Indian J Pathol Microbiol 2011;54:454-9.

Metabolic Parameters VariableSteatosis (+) (n=118) Steatosis (-) (n=232) p value Mean BMI (kg/m 2 ) <0.01 Mean FBS (mg/dL) Mean TG (mg/dL) Mean cholesterol (mg/dL) Mean insulin (IU/L) Median HOMA-IR2.7 ( )1.9 ( )0.048 Rastogi A. et al. Indian J Pathol Microbiol 2011;54: BMI: body mass index; FBS: fasting blood sugar; TG: triglycerides; HOMA-IR: Homeostatic Model of Assessment – Insulin Resistance

Histological Features Rastogi A. et al. Indian J Pathol Microbiol 2011;54: VariableSteatosis (+) (n=118) Steatosis (-) (n=232) p value Mean HAI score Mean fibrosis score HAI: histological activity index

Data in Medistra Hospital VariableSteatosis (+) (n=118) Steatosis (-) (n=232) p value Mean BMI (kg/m 2 ) <0.001 Waist circumference (cm) <0.001 Mean ALT (U/L) Log HBV-DNA (copies/mL) Liver stiffness (kPa) HBeAg-positive (%) Genotype C (%) Lesmana LA, et al. Acta Med Indones 2012;44:35-9.

Histological Features Fibrosis stage Inflammatory grade p = 0.849p = Lesmana LA, et al. Acta Med Indones 2012;44:35-9.

Predictors of Steatosis in CHB CountryNSteatosisPredictors Altlparmak, et al (2005)Turkey16439%Older age, BMI, high cholesterol and triglyceride Gordon, et al (2005)Australia1776%Waist circumference, FPG, C- peptide Thomopoulos, et al (2006)Greece23318%FPG, BMI> 25 kg/m 2 Bondini, et al (2007)USA6419%Obesity, waist circumference, hypergension, dyslipidemia, older age Cindoruk, et al (2007)Turkey14034%BMI, total cholesterol, hypertriglyceridemia Peng, et al (2008)China15327%BMI, Age ALT Rastogi, et al (2011)India35034%Triglyceride Lesmana, et al (2012)Indonesia17430%Waist circumference

Fatty Liver vs. SVR Rates Cindoruk M, et al. J Clin Gastroenterol 2007;41: FL did not affect IFN-based treatment outcomes (p > 0.005)

ALT HBeAg+ HBV DNA Immune Escape/ Reactivation Inactive Carrier Status HBeAg – Chronic HBV HBeAg + Chronic Hepatitis B Immune Tolerant Immune Control Immune Clearance Immune control – treatment not required Immune control – inactive disease HBeAg–

Summary: NAFLD in CHB NAFLD is commonly found in about one-third of patients. NAFLD in CHB is strongly associated with metabolic factors, e.g.: body mass index (BMI), obesity, insulin resistance, dyslipidemia. NAFLD is not associated with liver fibrosis or histological activity index. NAFLD may not affect treatment response. In patients with CHB and NAFLD with elevated ALT in clinical practice is not easy to distinguish whether the high ALT is due to CHB or NAFLD.

Current Evidence

Risk factors of FL in Chronic Hep C ParameterHCV (n=75)HCV+ FL (n=69)p value Obesity2552<0.05 Diabetes821<0.05 Hypertension1425<0.05 Hypertriglyceridemia1533<0.05 Metabolic syndrome2863<0.001 Fatty liver is associated with features of metabolic syndrome in patients with chronic hepatitis C virus infection. Sanyal AJ, et al. Am J Gastroenterol 2003;98:

IR and Liver Fibrosis in CHC Taura N, et al. Am J Gastroenterol 2006;101: Insulin resistance is associated with more advanced fibrosis in patients with chronic hepatitis C virus infection p = 0.002

HCV GENOTYPE DISTRIBUTION HCV genotype 1b is predominant in Indonesia Utama A, et al. Liver Int 2010;30: Subjects: 68 chronic hepatitis, 48 cirrhosis, and 34 HCC Method: core sequence analyses %

Relapse rate are higher in patients infected with HCV genotype 3 who have an RVR Shah SR, et al. Clin Gastroenterol Hepatol 2011;9:  RVR: rapid virologic response (HCV RNA <43 IU/mL at week-4 )  SVR: sustained virologic response (HCV RNA <15 IU/mL at week-48 p=0.001

Steatosis is the strongest independent predictor of relapse in patients infected with HCV genotype 3 who have an RVR Shah SR, et al. Clin Gastroenterol Hepatol 2011;9: OR: 3.0; 95%CI: 1,5-6.1; p=0.003 Steatosis vs. no steatosis HCV RNA > vs. < IU/mL BMI > vs < 30 kg/m2 Age > vs <45 years GGT > vs < ULN OR: 2.5; 95%CI: 1,0-6.3; p=0.04 OR: 2.2; 95%CI: 1,0-4.8; p=0.04 OR: 2.2; 95%CI: 1,2-4.2; p=0.02 OR: 2.1; 95%CI: 1,1-4.1; p=

HCV infection and Metabolic Syndrome There is no evidence for association between HCV infection and metabolic syndrome. The 2 conditions occur together at a higher rate than would occur by chance, although HCV infection has been associated with type2 diabetes mellitus. The serum lipid profile of patients with HCV infections is characterized by decreased level of cholesterol and sometimes triglycerides,in contrast to metabolic syndrome Negro F. Gastroenterology 2012;142:

HCV and Lipid Metabolism that may lead to steatosis of hepatocytes Negro F. Gastroenterology 2012;142:

HCV might affect insulin signaling in hepatocytes contributing to Insulin Resistance Negro F. Gastroenterology 2012;142:

Possible Clinical Outcomes Insulin resistance in CHC have substantial impact on the morbidity and mortality : Accelerated progression of liver fibrosis Increase type 2 diabetes Reduced virological response to antiviral therapy Increase incidence of cardiovascular events  need further study Bugianesi E, et al. J Hepatol 2012;56(Suppl ):S56-S65

Summary: NAFLD in CHC NAFLD is frequently found in CHC Its present is genotype specific, mostly genotype 1 and 3 Alcohol, central obesity, raised BMI are associated with more activity and more severe fibrosis Obesity reduces response to IFN-based treatment NAFLD may increase relapse rate among previously rapid virologic responders